Corcept Therapeutics (CORT) Tops Q4 EPS by 1c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $111.62 --0%
EPS Growth %: +393.8%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +393.8%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.28, $0.01 better than the analyst estimate of $0.27. Revenue for the quarter came in at $135.4 million versus the consensus estimate of $130.31 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
- Citi upgrades Old Dominion Freight Line to Buy with $223 target
- UBS Upgrades Feng Tay Enterprises (9910:TT) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
